Zelluna ASA (OSL:ZLNA)

Market Cap	606.83M +89.0%
Revenue (ttm)	n/a
Net Income	-140.71M
EPS	-7.08
Shares Out	26.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,882
Average Volume	102,859
Open	24.00
Previous Close	23.10
Day's Range	22.20 - 24.00
52-Week Range	8.20 - 35.80
Beta	n/a
RSI	53.05
Earnings Date	May 7, 2026

About Zelluna ASA

Zelluna ASA develops T-cell receptor (TCR) cellular immunotherapy products for the treatment of solid cancers. The company has a clinical partnership with Medpace Holdings, Inc. to support the clinical trial of ZI-MA4-1 (ZIMA-101); and collaboration with Etcembly Ltd for AI-enabled TCR engineering. The company was founded in 2016 and is based in Oslo, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 26
• Stock Exchange: Oslo Børs
• Ticker Symbol: ZLNA